The availability of reliable, specific, and high-quality antibodies is an ongoing challenge for Parkinson’s disease research. CST has partnered with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help identify gaps in antibody research tools and develop validated and reliable reagents to move PD research forward.
More than 10 million people worldwide are currently living with PD, yet much about the condition is poorly understood. Professionally, CST scientists are a passionate group of researchers who care deeply about understanding the underlying mechanisms of PD and enabling discovery research through the development of antibodies to critical targets. Personally, we are also driven by our own experiences with this debilitating neurological disease and are committed to facilitating the development of novel therapeutics.
As part of this partnership, CST scientists are working in collaboration with MJFF to develop and make available high-quality antibodies to important PD targets. These novel products will join our existing, extensive portfolio of antibodies and assay kits to interrogate key PD-associated proteins, including DJ-1 (PARK7), LRRK2/dardarin, α/β-synuclein (SNCA), and PINK1.
Explore the dopamine signaling pathway.
Identify and characterize disease-associated neuronal and glial cells.
Use the Hallmarks of NDG framework to study PD molecular biology.
Browse our broad portfolio of NDG research products.
Take control over your project with supply-stable monoclonal antibodies. Many of these products are also available carrier-free, or conjugated to fluorophores across the spectrum.
Ready-to-use ELISA Kits enable detection of endogenous protein expression.
The same Matched Antibody Pairs found in ELISA Kits are also available for purchase separately. Conjugation to biotin, Phycoerythrin (PE), and other fluorescent dyes is available. Matched Antibody Pairs are best suited for use in high-throughput ELISA-like technologies, such as MSD, Quanterix Simoa, AlphaLISA, TR-FRET, and more. Contact us for availability, lead times, and pricing.